|
The positive response of people towards stem cell technology and the lifting-up of ban on embryonic stem cell research will fuel the growth of the US stem cell market in future
By Shushmul Maheshwari RNCOS E-Services Pvt. Ltd. Email: press@rncos.com http://www.rncos.com/
Friday - June 5, 2009
The stem cell market in US is expected to grow at a CAGR of 84% during 2009-2012 to reach at around US$ 889 Million by 2012, says a new report "US Stem Cell Market Analysis" from RNCOS.
Investors Get 10 Stock Directories & Investor Newsletter for just $99 Year! Renewable energy, water, natural gas, mining and gold stocks, biotech stocks & more... Join us today and start investing!
Become an Investor Ideas Member
The optimistic approach of the patients suffering from severe diseases towards the adoption of stem cell technology will fuel the growth of the stem cell market in future. Also, the rise in healthcare spending, with large part of the population without any health insurance cover, is making the costly treatments unfavorable for the Americans.
The US soon realized the hidden potential in stem cell market and took timely moves to ensure stem-cell storage that led to the development of therapeutic banking technology segment. The country therefore is backed up with adequate infrastructure to support the use of stem cells for therapy and research purposes.
The country has achieved some important milestones in the therapy areas like bone marrow transplantation with the help of stem cell technology. The cellular therapeutics though smaller in size than therapeutics banking market is expected to grow comparatively fast during 2009-2012.
The US stem cell market presently has few orthopedic products. However, seeing its efficacy to cure a problem over the present available treatments, researches are going on to find out new therapeutic applications.
The market is also expected to witness a robust growth with the easing-off of the regulatory constraints and federal funding in 21 different embryonic stem cell lines. The embryonic stem cells have the ability to convert into different types o f tissues in the body and thus, they exhibit higher potential to cure a disease.
Our report "US Stem Cell Market Analysis" provides the rational analysis and extensive research on the stem cell market in the US. The report thoroughly examines the current industry trends which are adding to the growth in the country's stem cell market. The report also highlights various emerging therapy segments and their market potential to serve the population of the country more effectively.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM191.htm
Check DISCOUNTED REPORTS on: http://www.rncos.com
About RNCOS:
RNCOS, incorporated in the year 2002, is an industry research firm. We are a team of industry experts who analyze data collected from credible sources. We provide industry insights and analysis that helps corporations to take timely and accurate business decision in today's globally competitive environment.
Published at Investorideas.com Financial Article Feed : http://www.investorideas.com/RSS/feeds/II-Art.xml About InvestorIdeas.com: One of the first online investor resources providing in-depth information on renewable energy, greentech and water sectors.
Become an Investorideas.com Member Gain Exclusive Insight on Leading Sectors, Global Trends, and Insider Trading Ideas, News, Articles, renewable energy and water stocks directory. Learn more: http://www.investorideas.com/membership
Sign up for free newsletter, stock and sector news alerts at Investorideas.com click here: http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer: The views and opinions expressed in the research published are those of the individual companies and writers and not necessarily those of Investorideas.comŽ, or any of the industry sector portals . At the time of publication, writers may hold positions in the stocks or companies mentioned.
Investorideas.comŽ or any of the industry sector portals cannot assure accuracy of the research presented. Investors are encouraged to research and verify facts and under no circumstances is Investorideas.comŽ endorsing the content as a recommendation to buy or sell stock.

|